Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
October 29, 2025 Off

Trethera Successfully Completes Phase 1 Dose Escalation Trial Demonstrating Broad Therapeutic Window, Favorable Safety, and Confirmed Target Engagement

By GlobeNewswire

LOS ANGELES, Oct. 28, 2025 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for…

October 28, 2025 Off

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

By GlobeNewswire

BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage biotechnology…

October 28, 2025 Off

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

By GlobeNewswire

SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing…

October 28, 2025 Off

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

By GlobeNewswire

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) — Immunovant (Nasdaq: IMVT) today announced that it will report its financial results…

October 28, 2025 Off

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

By GlobeNewswire

BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced that it…

October 27, 2025 Off

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

By GlobeNewswire

MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) — Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced…

October 27, 2025 Off

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease

By GlobeNewswire

In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or…

October 27, 2025 Off

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

By GlobeNewswire

ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical…

October 27, 2025 Off

MapLight Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire

SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) — MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving…

October 27, 2025 Off

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

By GlobeNewswire

Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address…

Posts pagination

Previous 1 … 60 61 62 … 3,605 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine